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Abstract
Background: Comparisons of clinical trial findings in systematic reviews can be hindered by the heterogeneity of
the outcomes reported. Moreover, the outcomes that matter most to patients might be underreported. A core
outcome set can address these issues, as it defines a minimum set of outcomes that should be reported in all
clinical trials in a particular area of research. The objective in this study was to develop a core outcome set for
clinical trials of medication review in multi-morbid older patients with polypharmacy.
Methods: Firstly, eligible outcomes were identified through a systematic review of trials of medication review in
older patients (≥65 years) and interviews with 15 older patients. Secondly, an international three-round Delphi
survey in four countries involving patients, healthcare professionals, and experts was conducted to validate
outcomes to be included in the core outcome set. Consensus meetings were conducted to validate the results.
Results: Of the 164 participants invited to take part in the Delphi survey, 150 completed Round 1, including 55
patients or family caregivers, 55 healthcare professionals, and 40 experts. A total of 129 participants completed all three
rounds. Sixty-four eligible outcomes were extracted from 47 articles, 32 clinical trial protocols, and patient interviews.
Thirty outcomes were removed and one added after Round 1, 18 outcomes were removed after Round 2, and seven
after Round 3. Results were discussed during consensus meetings. Consensus was reached on seven outcomes, which
constitute the core outcome set: drug-related hospital admissions; drug overuse; drug underuse; potentially
inappropriate medications; clinically significant drug-drug interactions; health-related quality of life; pain relief.
Conclusions: We developed a core outcome set of seven outcomes which should be used in future trials of
medication review in multi-morbid older patients with polypharmacy.
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Background
Patients aged 65 and older are often exposed to poly-
pharmacy in a multi-morbidity context [1, 2]. This
increases medication costs and the risk of adverse drug
reactions [3–6]. Structured medication review has been
shown to be an efficient way to optimize prescribing for
older patients [7, 8]. Its impact on clinical, patient-
reported, and economic outcomes has been evaluated in
a wide range of randomized controlled trials (RCTs).
Also, several systematic reviews and meta-analyses have
been conducted to assess its effectiveness in various
settings [7–19]. The quality of conclusions has, however,
been limited by the heterogeneity of outcomes, among
other factors. Robust meta-analyses could be performed
for only a few outcomes, including hospitalization and
death [14–16, 20].
A core outcome set (COS) defines a minimum set of
outcomes to be reported in all clinical trials in a particu-
lar research area. The COS can (1) reduce heterogeneity
between trials, (2) lead to research that is more likely to
measure relevant outcomes, (3) enhance the value of
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evidence synthesis by reducing the risk of outcome
reporting bias, and (4) ensure that all trials report usable
information [21–23]. Outcome reporting bias is an
underrecognized problem that affects conclusions in
many systematic reviews [24–26]. Moreover, outcomes
that are highly relevant to older adults are often ignored
in RCTs [27, 28].
This work, part of the European OPtimising thERapy to
prevent Avoidable hospital admissions in the Multimorbid
elderly (OPERAM) project, aimed to develop a COS for




The Outcome Measures in Rheumatology (OMERACT),
Core Outcome Measures in Effectiveness Trials (COMET),
and Core Outcome Set-STAndards for Reporting (COS-
STAR) guidelines were used for developing and reporting
this COS [21, 29, 30]. The scope of the COS was ’Medication
review among patients aged 65 years and older with
polypharmacy (≥5 daily medications) and multi-morbidity
(≥2 chronic morbidities)’. The project was registered on the
COMET database (http://www.comet-initiative.org/studies/
details/806?result=true). Details on the study protocol have
been published elsewhere [31]. The COS-STAR checklist is
detailed in Additional file 1: Table S1.
The study was performed in four countries (Belgium,
Ireland, Switzerland, and the Netherlands). The medical
centers included tertiary academic medical centers with
a wide range of surgical and internal medicine special-
ties, including geriatric medicine (Belgium, Switzerland,
and the Netherlands), and a secondary medical center
specialized in geriatrics (Ireland). A steering committee
was set up with researchers from the four participating
medical centers.
Ethical approval
Ethical approval was obtained in Belgium and Ireland. In
the Netherlands and Switzerland, official ethical approval
was not required, as the ethics committees confirmed
that the relevant legislation was not applicable.
List of potential outcomes for inclusion in Delphi survey
As a first step, a systematic review identified all outcomes
previously used or planned to be used for evaluating the
effect of medication review among older patients. It was
achieved through an update of a recent systematic review
on medication review published by Lehnbom et al. [9]
combined with a systematic search in randomized clinical
trials registries and on the Cochrane Database. All data
extractions on outcomes were performed by two inde-
pendent reviewers. Any disagreement was resolved by
discussion and consensus. Details have been published
elsewhere [32].
In parallel, a qualitative study identified unknown and
relevant outcomes that should be included in the Delphi
survey. We held semi-structured one-to-one interviews
with patients and family caregivers. Patients aged ≥ 65
taking at least five different daily medications were
recruited from the geriatric outpatient clinic, the acute
geriatric ward, and other medical and surgical wards in
two Belgian teaching hospitals (purposive sampling).
Family caregivers assisting such patients were eligible for
inclusion. The interviews took the form of a discussion
about the patient’s medications, the perception of risks
and benefits of his/her medications, the concept of
medication review, and what he/she would expect from
a medication review. A topic guide was developed, pilot-
tested, and used by both interviewers (AS and OD).
Interviews were recorded and then transcribed verbatim.
Audio recordings of the interviews were analysed using
NVivo10®. Two independent researchers (a physician
and a psychologist) used an interpretative approach to
identify outcomes and outcome definitions based on
participants’ descriptions. The analysis focused on iden-
tifying a list of outcomes that are important to older
people. Analysts proceeded with coding, labelling, and
indexing of data to facilitate the process of identifying
relevant outcomes and outcome domains. Because it was
difficult for patients to respond readily to the notion of
outcome, analysts concentrated on going beyond a
simple cataloguing of outcomes to form a deeper under-
standing of what participants wanted and expected from
a medication review. They each worked individually,
then compared their findings and reached consensus on
a final report. Both analysts were experienced in qualita-
tive research and blind to the systematic review findings.
In a later stage, the main researcher (JBB), who per-
formed the systematic review and led the development
of the COS, reviewed the analysis reports and read the
transcripts. The three researchers met to discuss
findings, and any disagreement was resolved by discus-
sion and consensus. The results, including consensus
achieved by the two researchers and unsolved disagree-
ments, were further discussed with healthcare profes-
sionals and other researchers to validate a final list of
eligible outcomes for the Delphi survey.
Next, the results from the systematic review and the
qualitative study were merged into a list of outcomes
during a consultation exercise. Clinical experts and
researchers identified overlap between outcomes and
checked the medical and the plain language terms.
People without medical knowledge further improved the
plain language terms. The outcomes were classified into
domains and areas according to the OMERACT classifi-
cation [29]. The plain language terms and explanations
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were tested for understandability with two older patients
(aged 86 and 92) and thereby improved. This provided a
final list of outcomes and definitions.
Outcomes were selected regardless of feasibility issues
during the systematic review, qualitative study, and
consultation exercise. The purpose was to identify all
possibly relevant outcomes, particularly for patients. If a
feasibility issue was stressed by participants during the
Delphi survey, this issue was discussed during consensus
meetings until consensus was achieved.
Delphi questionnaire survey
Three groups of stakeholders were drawn (164 individuals).
Participants in each group were recruited in the four
European countries by the medical centers, and additional
external participants were recruited worldwide for Group 3.
Group 1 consisted of family caregivers, patients aged 65 to
80, and patients older than 80. Group 2 consisted of health-
care professionals: general practitioners (GPs), community
and hospital pharmacists, geriatricians, specialists in in-
ternal medicine, and nurses. Group 3 (the ’expert’ group)
included medication review researchers (recruited based on
their publication’s profile, assessed via Scopus®) and
researchers in other relevant areas (e.g. sociologists of
aging), representatives of scientific organizations, and
policymakers. We aimed for proportions of 35%, 35%, and
30% of participants from Groups 1, 2, and 3, respectively.
Participants in Group 1 were identified from researchers’
professional networks, local associations for older people,
and personal networks. In order to ensure enough variabil-
ity among patients, we purposively selected participants
who varied in terms of age, gender, and practice setting.
Participants in Group 2 were recruited among healthcare
professionals from the academic hospital, other secondary
non-academic hospitals, ambulatory care centers, and nurs-
ing homes connected or not to the local coordinating center.
The online questionnaire was developed by a company
(WorldAPP®) specializing in online surveys (see http://
app.keysurvey.fr/f/1038815/5ded/).1 We expected com-
pletion of the online survey to be difficult for some older
patients. All centers therefore proposed to older patients
or family caregivers to complete the questionnaire with
the help of a local interviewer at home or during a con-
sultation. The other stakeholders answered it online.
The Delphi process consisted of three rounds of ques-
tionnaires. Participants who did not participate in Round
1 were not invited for Round 2, and those who did not
participate in Round 2 were not invited for Round 3
[33]. In Rounds 1 and 2, participants were asked to score
each outcome on a scale from 1 (not important) to 9 (of
critical importance). Outcomes considered as ’very
important’ (rating 7 to 9) by ≥ 75% of participants in at
least one stakeholder group were presented in the subse-
quent Delphi round. Additional outcomes suggested by
Round 1 participants were presented in Round 2, if rele-
vant. In Round 2, responses from Round 1 were summa-
rized and were presented to the participants with their
own results and the mean results of each stakeholder
group. In Round 3, all participants were asked whether
the outcomes should be systematically measured in all
studies of medication review in the elderly (YES/NO).
An outcome was eligible for inclusion in the COS if ≥ 75%
of participants in at least one stakeholder group rated it
YES in Round 3.
Protocol adaptations
During the study, two deviations from the original
protocol were needed. In the first, outcomes that did not
meet the consensus rating for inclusion (i.e. ≥ 75% rating
of 7 to 9 in at least one stakeholder group) were
removed at each stage. The original protocol rule was to
remove outcomes that met a consensus rating for exclu-
sion (i.e. ≥ 75% rating of 1 to 3 in all groups). This
change was motivated by high ratings by participants,
comments of participants who felt the questionnaire was
too long, and those of local interviewers who reported
that most older participants felt tired at the end of the
first questionnaire (Round 1). In the second deviation,
the rating scale was replaced by a direct YES/NO ques-
tion in Round 3 to further limit the number of outcomes
in the final COS. Both deviations were discussed with
participants during consensus meetings and with external
experts and were approved by the steering committee.
Consensus meetings
After Round 1 and Round 2, feedback was retrieved by
local interviewers for older patients and by comments
made in the online questionnaire by some other pa-
tients, family caregivers, healthcare professionals, and
the experts. Most comments made by the experts were
very clear and precise. All comments were summarized
and discussed during two consensus meetings to agree
on the list of outcomes for the next round: (1) with
healthcare professionals from the Belgian center and (2)
with the steering committee. Final decisions were taken
by the steering committee.
After Round 3, three consensus meetings took place, in-
cluding a face-to-face meeting with patients and caregivers
in Belgium, a conference call with healthcare professionals
from the Belgian center, and a conference call with medica-
tion review experts and the steering committee members.
Due to language issues, patients and family caregivers from
other centers were not invited. The results of each round
were presented, with the consensus results from Round 3
analyses used as the starting point for discussion. The goal
was to comprehensively address points for discussion and
to agree on the final COS. Interaction between participants
from the three groups was indirect: the feedback and
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opinions of each were transmitted to the others by the coor-
dinators (JBB and AS). A final consensus meeting was held
by conference call for the steering committee members and
primary local investigators of the OPERAM project.
Results
List of eligible outcomes
The systematic review identified 57 eligible outcomes
from 47 published studies and 32 RCT protocols (see
Additional file 2: Additional references). Fifteen interviews
were conducted with patients and family caregivers. The
interpretative approach identified 19 outcomes, seven of
which had not been identified in the systematic review. A
final list of 64 (57 + 7) eligible outcomes was obtained by
merging the two lists. These outcomes were grouped into
eight health domains according to the recommendations
of the OMERACT Filter 2.0 (Additional file 3: Table S2).
Delphi survey
Of the 164 participants invited, 150 completed Round 1,
including 55 patients or family caregivers, 55 healthcare
professionals, and 40 experts. The participant character-
istics are detailed in Additional file 4: Table S3. Nearly
half the patients were older than 80, and more than one
third of the healthcare professionals were GPs. The four
centers recruited 126 participants, divided evenly
between Belgium (n = 33, 26%), Ireland (n = 30, 24%), the
Netherlands (n = 32, 25%), and Switzerland (n = 31, 25%).
The 24 remaining participants were specialized medication
review researchers from Australia (n = 3), Europe (n = 13),
and North America (n = 8).
The flow of participants and outcomes is presented in
Fig. 1. Of the 150 who completed Round 1, 136 com-
pleted Round 2, and 129 completed Round 3. The over-
all attrition rate was 14%. After Round 1, 31 outcomes
did not meet the consensus rating for inclusion in any of
the three groups, including the outcome ’death’. Partici-
pants proposed 32 other outcomes. Most overlapped
with outcomes proposed during Round 1. One outcome
expanded the concept of treatment burden, which was
split into two distinct outcomes: ’drug regimen complex-
ity’ and ’number of drugs taken daily’. The consensus
meeting decided to remove 30 outcomes; ’death’ was
kept for Round 2 at the request of two stakeholder
groups, and the ’drug regimen complexity’ outcome was
added. Thirty-five outcomes were presented to the par-
ticipants in Round 2.
After Round 2, 18 outcomes did not meet the consensus
rating for inclusion in any of the three groups, including
’death’, and these outcomes were therefore removed. The
consensus meeting decided to keep 17 outcomes in Round
3. The direct question in Round 3 (YES/NO) led to the
selection of 10 outcomes, presented in Table 1. Two were
selected by all three groups: ’drug-related hospital admis-
sions’ and ‘serious adverse drug events’.
International consensus
Of the 11 patients or family caregivers who participated in
Round 3 in Belgium, six agreed to participate in a face-to-
face consensus meeting. All were women: three aged 65 to
80 and three older than 80. Of the 14 healthcare profes-
sionals who participated in Round 3 in Belgium, six (three
GPs, one hospital physician, and two pharmacists) agreed
to participate in a conference call consensus meeting. Due
to limited availability, no researcher attended the consensus
meeting. However, three specialized medication review
researchers agreed to participate in a one-hour conference
call to discuss the results.
The comments and consensus obtained during the
meetings and conference calls were unambiguous for 11
of the 17 outcomes reviewed. Four were definitively
included and seven removed. The six remaining outcomes
were discussed before consensus and a final decision were
reached (Table 1). For example, 89% of participants in the
patient group had selected ’pain relief ’ for inclusion in the
COS, whereas 77% of participants in the expert group had
rejected it. After discussion, a consensus was reached on
including this outcome in the final COS. A summary of
the discussions for these six outcomes is given in
Additional file 5: Table S4.
Final core outcome set
The final COS, with seven outcomes, is presented in
Table 2. Three domains are covered: adverse events (one
outcome), medication use (four outcomes), and patient-
reported outcomes (two outcomes). Two other outcomes
were considered highly relevant but were not included in
the final COS because of feasibility issues: ’serious adverse
drug reaction’ and ’suitability of drug dosage according to
renal function’ (Additional file 5: Table S4).
Discussion
Summary
This study aimed to identify outcomes of great relevance
to clinical trials of medication review in multi-morbid
older patients with polypharmacy from different stake-
holders’ perspectives. For this purpose, the study used
methodological guidance of initiatives like COMET and
OMERACT [21, 29] and a Delphi survey of 129 partici-
pants from four European countries along with experts
from three continents. The opinions of old and very old
patients, healthcare professionals, and experts were
acknowledged equally, a feature lacking in most COS
research. Consensus was achieved on seven outcomes to
include in the COS, which can be recommended for
future use in clinical trials.
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Discussion of the included and excluded outcomes
Domain: adverse events
The two outcomes with the highest degree of agreement,
‘drug-related hospital admissions’ and ‘serious adverse
drug reaction’, were related to the adverse events do-
main. More than 75% of participants in all three stake-
holder groups selected these outcomes. The ’serious
adverse drug reaction’ outcome could not be included in
the final COS because its measurement outside the hos-
pital environment has seldom been investigated [34] and
would not be feasible in all RCTs on medication review.
Moreover, drug-related hospital admission represents
one component of serious adverse drug reactions, lead-
ing to an overlap between the two outcomes. Although
reducing drug-related adverse events is a major goal of
medication reviews, this outcome was poorly investi-
gated in previous RCTs. In a systematic review, only 7 of
47 studies reported data on drug-related admissions
[32]. Serious adverse drug reactions were reported in
only one of the 47 studies, probably because of the feasi-
bility issue [35].
Domain: medication use
Four of the seven outcomes selected in the final COS
relate to medication use: ‘overuse’, ‘underuse’, ‘potentially
inappropriate medications’, and ‘clinically significant
drug-drug interactions’. Together these outcomes cover
the concept of appropriateness of prescriptions. The
effect of a medication review on the appropriate use of
medication in older patients has mostly been evaluated
through more global measurement tools such as drug-
related problems or the Medication Appropriateness
Index [7, 17, 32]. Underuse, overuse, and clinically sig-
nificant drug-drug interactions were reported as separate
Fig. 1 Diagram showing the flow of participants and outcomes during the three rounds of the Delphi survey and the last consensus meeting
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Table 1 Results of Round 3 of the Delphi survey and of the consensus meetings
Domain Outcomea Delphi survey, Round 3 Consensus meetings
(% answering YES)b
Patients HCPs Experts Discussion required before
final inclusion
Final decision
Medication use Unnecessary drugs (overuse) 69 76 97 IN
Underuse 70 73 83 IN
Clinically significant drug-drug interaction 100 92 71 IN
Suitability of drug dosage according
to renal function
70 88 57 Yes Feasibility issue
Potentially inappropriate medications 55 68 68 Yes IN
Measurement of appropriateness 80 60 75 Yes OUT
Compliance with medication 62 76 67 Yes OUT
Use of healthcare resources Hospitalization
(all causes of hospitalization)
62 55 35 OUT
Adverse events Drug-related hospital admissions 83 86 84 IN
Adverse drug reaction 70 67 57 OUT
Serious adverse drug reaction 98 94 77 Yes Feasibility issue
Adverse drug withdrawal event 68 68 57 OUT
Patient-reported outcomes Quality of life 93 71 67 IN
Pain relief 89 49 23 Yes IN
Process evaluation Elicitation and consideration
of patient preference
65 69 56 OUT
Level of satisfaction of the patient’s GP
with communication on medication change
61 65 37 OUT
Patient’s satisfaction with the information on his/
her medication treatment
69 60 62 OUT
aBased on the 17 outcomes selected after Round 2
bBoldface indicates ≥ 75% YES ratings
Abbreviation: HCP healthcare provider
Table 2 Final core outcome set with definitions of the outcomes
Domain Outcome Definition
Adverse events Drug-related hospital admissions Hospitalization due to an adverse drug event: harm due to an adverse drug
reaction or a medical error related to overuse, underuse, or misuse of prescription
and non-prescription medications and which is the main reason for or
contributes to hospital admission of a patient
Medication use Overuse The use or prescription of more drugs than clinically needed, including
(1) any drug prescribed or used without an evidence-based clinical indication;
(2) therapeutic duplication; (3) medication prescribed or used beyond the
recommended duration
Underuse A failure to prescribe drugs that are indicated, including (1) omission of an
evidence-based drug; (2) too short a duration
Potentially inappropriate medications Drugs with risk of adverse drug reactions exceeding their expected clinical
benefit to patients, particularly when safer therapeutic alternatives are available
to treat the same condition [40]
Clinically significant DDI A clinically significant DDI is defined as having a significant severity rating
according to the drug interaction compendia used in the study (e.g. Drug
Interaction Facts or Micromedex) [41]
Patient-reported outcomes Health-related quality of life Personal health status: HRQoL usually refers to aspects of our lives that are
dominated or significantly influenced by our mental or physical well-being
Pain relief Whether pain has improved over the course of the trial
Abbreviations: HRQoL Health-related quality of life, DDI drug-drug interaction
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measures in only 6%, 6%, and 9%, respectively, of pro-
spective studies on medication review in older patients
[32]. Interestingly, the number of drugs was not consid-
ered a very important outcome by any group and did
not qualify for Round 3. Quality, it seems, matters more
than quantity.
Domain: patient-reported outcomes
Two of the seven outcomes in the final COS were
patient-reported outcomes. There was a clear consensus
among stakeholder groups on including ‘health-related
quality of life’. This outcome has been reported in nu-
merous published studies of medication review in older
patients [17, 19, 32]. However, the inclusion of ‘pain re-
lief ’ in the COS was more controversial. This outcome
had never been investigated in previous studies and was
identified during the qualitative study. It may be argued
that it is only pertinent to a small proportion of patients.
However, chronic pain symptoms affect more than half
of all people aged ≥ 65 and are associated with negative
clinical outcomes, and most older patients with chronic
pain syndromes take analgesics [36–38]. More than 75%
of older patients who participated in the Delphi survey
saw this outcome as very important in all three rounds.
The consensus meeting concluded that we cannot ask
older patients their opinions and then reject the results
when they do not correspond with experts’ views [39].
Implications for future research
Effectiveness of medication review in older patients has
most often been evaluated through outcomes related to
healthcare use and mortality, such as all-cause hospitali-
zations, length of hospital stay, emergency department
visits, and all-cause deaths [11, 15, 16, 20]. These out-
comes were not considered essential by most stake-
holders in our Delphi survey, including older patients.
This result highlights the importance of developing a
COS that avoids reductive conclusions based on out-
comes selected by researchers only. Most outcomes in-
cluded in our COS have been underreported in previous
RCTs of medication review. We contend, therefore, that
efforts should be made in the future to provide data on
these outcomes, to determine more comprehensively the
effectiveness of medication review in older patients. We
did not ask participants to consider the feasibility of
measuring the outcomes during the Delphi survey.
Future research should determine which measurement
tool is suitable for each outcome.
Strengths and limitations
This is the first Delphi study to explore international,
multi-stakeholder, and multidisciplinary consensus on
core outcomes to be reported in clinical trials of medica-
tion review in older patients with multi-morbidity and
polypharmacy. The strengths of this study include the
following: (1) use of methods following the guidance of
initiatives like COMET and OMERACT [21, 29]; (2) the
large number of older and very old patients involved; (3)
interviews with very old patients to increase participa-
tion; (4) a large expert panel of stakeholders representing
various disciplines and countries; (5) giving participants
the opportunity to comment on each choice; (6) low
attrition rate; (7) rigorous reporting of methods and
results according to COS-STAR guidelines [30].
Our study has some limitations. Departing from the
protocol, we had to adapt the methods which were used
to obtain consensus during the study. These changes
were discussed and validated with the steering commit-
tee, the OPERAM research team, and two external
experts in COS development. This was in line with the
existing guidelines for COS development, which do not
recommend one specific method but state that several
methods can be used and mixed if necessary to achieve
consensus according to the specific needs of the study
[21, 29]. Moreover, Delphi surveys are flexible, with vari-
ous recognized ways of measuring consensus [33]. Our
choices were made in order to combine scientific rigor
with pragmatism and relevance. Finally, patients and
caregivers included in the qualitative study and in the
consensus meeting were only from Belgium. The health-
seeking culture and attitudes towards polypharmacy may
vary across countries, and some comments or consensus
achieved by Belgian participants may be specific to their
culture or the Belgian health organization. However, the
Delphi study included numerous patients and healthcare
professionals from the four countries involved in the
study, in addition to experts from several countries,
which implies a real international perspective in the
development of this COS.
Conclusions
A consensus-based COS for medication review in
older patients with multi-morbidity and polypharmacy
was developed and included the following seven out-
comes: (1) drug-related hospital admissions; (2) drug
overuse; (3) drug underuse; (4) potentially inappropri-
ate medications; (5) clinically significant drug-drug
interactions; (6) health-related quality of life; (7) pain
relief. A COS will only have an impact if it is consist-
ently implemented in most trials of relevance in any
given area of research. Trialists, regulators, funding
agencies, and journals publishing clinical trials in the
area of multi-morbidity and polypharmacy in late life
should, we believe, aim to ensure that the appropriate
COS is used. Further research should establish which
instruments are the most appropriate for measuring
these core outcomes.
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Endnotes
1In this online test version, the user chooses the language,
participant category, and age group before accessing the
questionnaire. During the Delphi survey, these questions
were pre-filled and hidden. The participants had direct
access to the questionnaire in the right form and the appro-
priate language.
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